Tango Therapeutics Appoints Robert Azelby to Board of Directors
Tango Therapeutics appointed Robert Azelby to its Board of Directors, adding over three decades of biopharmaceutical leadership and oncology commercialization experience. Mr. Azelby previously served as CEO of Eliem Therapeutics and Alder BioPharmaceuticals and oversaw Amgen's $6 billion oncology portfolio, providing expertise relevant to Tango's current stage.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.